Reneuron Limited

To transfer innovative and commercially viable technological capabilities for labeling and imaging small biological particles, tracking their dispersal in the body after administration, and developing entirely new therapeutic modality in a lethal disease and an area of urgent medical need.

"Our project is a collaboration between ReNeuron Ltd, a well-established British stem cell therapy company and the Department of Advanced Therapies at the National Institute for Biological Standards and Control. ReNeuron has created an immortalised neural stem cell line called CTX, which is presently undergoing clinical trials as a transplant treatment fo...

ReNeuron is a biotechnology company that is experienced in developing cell therapy treatments for degenerative diseases such as stroke rehabilitation and diseases of the retina, such as retinitis pigmentosa (RP), for which there are no known treatments. In RP, the light detecting photoreceptor cells in the eye die gradually over a period of time, and the ...

This project will develop a next generation industrialised cGMP platform for the production of ReNeuron's allogeneic stem cell products which target significant, growing areas of unmet clinical need. The recent Advanced Therapy Medicinal Products Taskforce of the Medicines Manufacturing Industrial Partnership has identified that the ATMP industry is at a ...

ReNeuron is a leading UK regenerative medicine company currently conducting clinical trials with a novel human neural stem cell (hNSC) product for the treatment of stroke and limb ischaemia. These stem cells also produce small parcels of biologic material called exosomes. CTX-derived exosomes have been found to have functional properties in laboratory mod...

We plan to develop a novel ‘living nerve growth guide’ as an off the shelf therapy to treat peripheral nerve injury, which can cause lifelong pain and disability and is a significant unmet medical need. Our therapy would substitute for an autograft, the current ‘gold standard’ for peripheral nerve repair. Partners TAP Biosystems and The Open University ha...

Disability affects approximately 50% of stroke survivors due to permanent loss of brain tissue. ReNeuron is testing the effectiveness of a unique stem cell product, called CTX, in disabled stroke patients. ReNeuron has developed CTX from human brain stem cells, with cell banks established to provide the large quantities needed for clinical use. The safety...

Blinding diseases are devastating and costly to manage. Currently no treatments exist for inherited forms of blindness, such as Retinitis Pigmentosa (RP), where onset can begin in early childhood. In patients with RP, there are genetic defects in the light-detecting photoreceptor cells of the retina. Without any treatment options available, RP is severely...

This project is led by ReNeuron, a leading UK-based biotechnology business developing stem cell therapies. Critical limb ischaemia, a significant unmet medical need, is the end-stage of peripheral artery disease, resulting in poor blood flow (usually in the lower limb). The leading risk factor for this disease is Type II diabetes which has become an incre...